Adalimumab

• An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting
  2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
• An open-label randomized trial COmparing staNdard of care versus Treat to target with telemonitoRing and patient education in patients with … Recruiting
  2023-507256-76-00 Phase IV 1 country Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif
• A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Ante… Recruiting
  2023-505811-18-00 Phase III 3 countries Eli Lilly & Co.
• Stopping anti-TNF treatment in Crohn's and Colitis patients in remission Recruiting
  2024-513299-17-00 Phase IV 1 country Region Skane
• RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting
  2024-516704-41-00 Phase III/IV 1 country Les Hopitaux Universitaires De Strasbourg
• Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point… Ended
  2024-511530-12-01 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib V… Ended
  2022-502578-18-00 Phase III/IV 11 countries Abbvie Deutschland GmbH & Co. KG
• A randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to Compare Efficacy and Safety of ant… Ended
  2024-515557-22-00 Phase IV 1 country Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
• Efficacy of Abatacept vs Adalimumab in Early, Autoantibody positive Rheumatoid Arthritis (RA) and who did not respond well to methotrexate. Ended
  2023-506450-20-00 Phase III 6 countries Bristol-Myers Squibb Services Unlimited Company
• A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juven… Ended
  2023-507184-19-00 Phase III 7 countries Eli Lilly & Co.
• CoCroS trial Ended
  2024-516002-33-01 Phase IV 1 country Universiteit Maastricht
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth… Ended
  2022-501017-31-00 Phase III 17 countries Abbvie Deutschland GmbH & Co. KG
• PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease Ended
  2024-513647-86-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended
  2023-506655-19-00 Phase II 7 countries Genentech Inc.
• Investigating the safety, feasibility, and optimal dose of Adalimumab-680LT in IBD – GUIDE study Ended
  2023-508391-11-00 Phase I (FiH) 1 country Universitair Medisch Centrum Groningen
• Pilot study RCT anti-TNF Adalimumab versus placebo in fasciotomy Dupuytren contracture Ended
  2023-503701-11-00 Phase III 1 country UZ Leuven
• CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIM… Ended
  2024-513123-17-00 Phase III 1 country Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 Phase IV 15 countries Eli Lilly & Co.
• A Multi-Center, Open-Label Study of Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Ped… Ended
  2023-504711-32-00 Phase III 2 countries AbbVie Deutschland GmbH & Co. KG

Showing 25–43 of 43 trials